Pharmaceutical Firm Zydus Cadila signed Agreement with Pieris AG

Oct 16, 2013 15:24 IST

Pharmaceutical firm Zydus CadilaPharmaceutical firm Zydus Cadila on 16 October 2013 signed a drug development and commercialisation agreement with Germany’s Pieris AG for a new therapeutic protein molecule called Anticalin. The agreement brings together Pieris’ drug discovery and early development capabilities with Zydus’ expertise in biologics development, regulatory affairs and biologics manufacturing.

Zydus has been given exclusive marketing rights in India and several other emerging markets, while Pieris maintains exclusive marketing rights in key developed markets.

The most advanced programme in their collaboration is PRS-110, a target which is increasingly becoming valued across a broad spectrum of tumours.
Through the agreement the companies try to develop candidates to proof-of-concept and will explore out-licensing opportunities in Pieris’ territories.

Is this article important for exams ? Yes17 People Agreed
Read more Current Affairs on: Zydus Cadila , Pieris AG , Pharmaceutical

DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK